Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation

被引：12
|
作者：
Fang, Wenfeng [1 ]
Huang, Yihua [1 ]
Gan, Jiadi [1 ]
Shao, Yang W. [2 ]
Zhang, Li [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Med Oncol,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Nanjing Geneseeq Technol Inc, Nanjing, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
基金：
国家重点研发计划;
关键词：
D O I：
10.1016/j.jtho.2019.05.023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E220 / E221
页数：2
相关论文
共 50 条
  • [1] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lin, Ling
    Wu, Xiaomai
    Yan, Shuangquan
    Zhu, Yefei
    Yan, Zhengqing
    Lv, Dongqing
    Ge, Hongfei
    [J]. ONCOTARGETS AND THERAPY, 2020, 13 : 9753 - 9757
  • [2] Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
    Lv, D.
    Lin, L.
    Wu, X.
    Yan, S.
    Ge, H.
    Yan, Z.
    Wang, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S634 - S634
  • [3] Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    Urban, Laszlo
    Doczi, Robert
    Vodicska, Barbara
    Tihanyi, Dora
    Horvath, Magdolna
    Kormos, Dora
    Takacs, Istvan
    Papai-Szekely, Zsolt
    Poka-Farkas, Zsuzsanna
    Varkondi, Edit
    Schwab, Richard
    Hegedus, Csilla
    Valyi-Nagy, Istvan
    Petak, Istvan
    [J]. CLINICAL LUNG CANCER, 2021, 22 (01) : E112 - E115
  • [4] Durable response to immunotherapy plus chemotherapy in a patient with untreated, brain-metastatic, EGFR exon 20 insertion mutation lung adenocarcinoma A case report
    Nong, Jingying
    Gu, Yanfei
    Yao, Shuyang
    Zhang, Yi
    [J]. MEDICINE, 2021, 100 (29) : E26650
  • [5] Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
    Chen, Xuesong
    Zha, Wangjian
    Su, Mei
    Meng, Nan
    Cao, Shuliang
    Niu, Beifang
    Qi, Xu
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [6] Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib A case report
    Cai, Yangyang
    Wang, Xu
    Guo, Ye
    Sun, Chao
    Xu, Yinghui
    Qiu, Shi
    Ma, Kewei
    [J]. MEDICINE, 2019, 98 (01)
  • [7] A Case of a Patient Harboring an EGFR Insertion of Exon 20 and Long Lasting Clinical Response to Afatinib
    Lorandi, V.
    Macedo, G.
    Goncalves, V. K.
    Piccoli, R.
    Stefani, S.
    Gelatti, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2137 - S2138
  • [8] Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
    van Veggel, Bianca
    de Langen, Adrianus J.
    Hashemi, Sayed M. S.
    Monkhorst, Kim
    Heideman, Danielle A. M.
    Thunnissen, Erik
    Smit, Egbert F.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1222 - 1226
  • [9] An uncommon EGFR exon 25 mutation in a patient with lung adenocarcinoma successfully treated with Afatinib
    Kunz, J.
    Christopoulos, P.
    Grosch, H.
    Kunz, J.
    Thomas, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 109 - 109
  • [10] Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations
    Hasegawa, Hanako
    Yasuda, Hiroyuki
    Hamamoto, Junk
    Masuzawa, Keita
    Tani, Tetsuo
    Nukaga, Shigenari
    Hirano, Toshiyuki
    Kobayashi, Keigo
    Manabe, Tadashi
    Terai, Hideki
    Ikemura, Shinnosuke
    Kawada, Ichiro
    Naoki, Katsuhiko
    Soejima, Kenzo
    [J]. LUNG CANCER, 2019, 127 : 146 - 152
12345